Syndax Pharmaceuticals, Inc.SNDXNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-9.56%
↓ 190% below average
Average (39q)
10.61%
Historical baseline
Range
High:100.20%
Low:-30.96%
CAGR
-0.8%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -9.56% |
| Q2 2025 | 0.96% |
| Q1 2025 | -5.94% |
| Q4 2024 | -7.67% |
| Q3 2024 | 45.87% |
| Q2 2024 | -13.87% |
| Q1 2024 | 2.48% |
| Q4 2023 | 41.03% |
| Q3 2023 | 12.44% |
| Q2 2023 | 2.08% |
| Q1 2023 | 6.95% |
| Q4 2022 | 18.36% |
| Q3 2022 | -9.53% |
| Q2 2022 | -0.96% |
| Q1 2022 | 25.62% |
| Q4 2021 | -6.66% |
| Q3 2021 | 51.78% |
| Q2 2021 | -22.86% |
| Q1 2021 | 40.90% |
| Q4 2020 | 7.73% |
| Q3 2020 | 31.66% |
| Q2 2020 | 14.44% |
| Q1 2020 | 0.63% |
| Q4 2019 | -4.24% |
| Q3 2019 | -19.26% |
| Q2 2019 | 8.96% |
| Q1 2019 | -28.71% |
| Q4 2018 | 12.25% |
| Q3 2018 | -5.09% |
| Q2 2018 | -3.18% |
| Q1 2018 | -7.59% |
| Q4 2017 | 36.19% |
| Q3 2017 | 23.59% |
| Q2 2017 | 3.25% |
| Q1 2017 | 12.72% |
| Q4 2016 | -30.96% |
| Q3 2016 | 100.20% |
| Q2 2016 | 28.10% |
| Q1 2016 | 85.00% |
| Q4 2015 | -12.84% |